Rakshit Drugs Revenue and Competitors
Estimated Revenue & Valuation
- Rakshit Drugs's estimated annual revenue is currently $25.5M per year.
- Rakshit Drugs's estimated revenue per employee is $201,000
Employee Data
- Rakshit Drugs has 127 Employees.
- Rakshit Drugs grew their employee count by 7% last year.
Rakshit Drugs's People
Name | Title | Email/Phone |
---|
Rakshit Drugs Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $21.7M | 108 | 6% | N/A | N/A |
#2 | $116.6M | 580 | 5% | N/A | N/A |
#3 | $29.7M | 148 | -12% | N/A | N/A |
#4 | $67.9M | 338 | 12% | N/A | N/A |
#5 | $23.5M | 117 | 13% | N/A | N/A |
#6 | $24.1M | 120 | 15% | N/A | N/A |
#7 | $101.5M | 505 | -8% | N/A | N/A |
#8 | $171.9M | 855 | 24% | N/A | N/A |
#9 | $27.7M | 138 | 5% | N/A | N/A |
#10 | $9M | 45 | -6% | N/A | N/A |
What Is Rakshit Drugs?
Rakshit Drugs Pvt. Ltd. is a pharmaceuticals company based out of Rakshit House,425/3RT, D.No. 7-1-621/328, S.R. Nagar, Hyderabad, India.
keywords:N/AN/A
Total Funding
127
Number of Employees
$25.5M
Revenue (est)
7%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Rakshit Drugs News
2022-04-20 - Amlodipine Besilate Market Size, Share, Growth 2022-2030| Key ...
VPL Chemicals; Rakshit Drugs; Moehs; Dr. Reddy's; Cadila Pharmaceuticals; Amsal Chem; Changzhou Yabang Pharmaceutical; Cipla; Tapi Teva; Suan.
2022-04-06 - Ukrainian officials begin urging evacuations amid reports of new ...
Sami Rakshit, director of Finnish Customs' Enforcement Department, ... decontamination equipment and drugs that could boost its defenses in...
2022-04-06 - 20,488 ghost companies detected in Hyderabad, 3rd-highest in India
Vizag GST Commissionerate booked a case against Hyderabad-based Rakshit drugs private limited, Virupaksha Organics Limited,...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $17.8M | 127 | 34% | N/A |
#2 | $23M | 128 | -1% | N/A |
#3 | $18.7M | 129 | -1% | N/A |
#4 | $18.1M | 129 | 28% | N/A |
#5 | $18.7M | 129 | 12% | N/A |